Literature DB >> 26977209

A primer on tumour immunology and prostate cancer immunotherapy.

Runhan Ren1, Madhuri Koti2, Thomas Hamilton2, Charles H Graham3, Jasmir G Nayak4, Jas Singh4, Darrel E Drachenberg4, D Robert Siemens3.   

Abstract

Entities:  

Year:  2016        PMID： 26977209      PMCID： PMC4771561          DOI： 10.5489/cuaj.3418

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  55 in total

Review 1.  Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.

Authors:  Przemysław Holko; Paweł Kawalec
Journal:  Expert Rev Anticancer Ther       Date:  2014-01       Impact factor: 4.512

2.  The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Authors:  Fred Saad; Kim N Chi; Antonio Finelli; Sebastien J Hotte; Jonathan Izawa; Anil Kapoor; Wassim Kassouf; Andrew Loblaw; Scott North; Ricardo Rendon; Alan So; Nawaid Usmani; Eric Vigneault; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 4.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

Review 5.  Immune-mediated mechanisms influencing the efficacy of anticancer therapies.

Authors:  Seth B Coffelt; Karin E de Visser
Journal:  Trends Immunol       Date:  2015-04       Impact factor: 16.687

Review 6.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

7.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 8.  Regulatory T cells in tumor immunity.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

9.  Clinical safety of a viral vector based prostate cancer vaccine strategy.

Authors:  Philip M Arlen; Lisa Skarupa; Mary Pazdur; Mahesh Seetharam; Kwong Y Tsang; Douglas W Grosenbach; Jarett Feldman; Diane J Poole; Mary Litzinger; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Howard Parnes; John Wright; William Dahut; Jeffrey Schlom; James L Gulley
Journal:  J Urol       Date:  2007-08-16       Impact factor: 7.450

Review 10.  Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.

Authors:  Lawrence Fong; Eric J Small
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544
View more
  5 in total

1.  Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Authors:  Matthew J Atherton; Kyle B Stephenson; Fanny Tzelepis; David Bakhshinyan; Jake K Nikota; Hwan Hee Son; Anna Jirovec; Charles Lefebvre; Anna Dvorkin-Gheva; Ali A Ashkar; Yonghong Wan; David F Stojdl; Eric C Belanger; Rodney H Breau; John C Bell; Fred Saad; Sheila K Singh; Jean-Simone Diallo; Brian D Lichty
Journal:  Oncoimmunology       Date:  2018-03-27       Impact factor: 8.110

2.  Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.

Authors:  T J Mai; R Ma; Z Li; S C Bi
Journal:  Braz J Med Biol Res       Date:  2016-10-24       Impact factor: 2.590

Review 3.  Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.

Authors:  Marlena Janiczek; Łukasz Szylberg; Anna Kasperska; Adam Kowalewski; Martyna Parol; Paulina Antosik; Barbara Radecka; Andrzej Marszałek
Journal:  J Immunol Res       Date:  2017-10-03       Impact factor: 4.818

4.  Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer.

Authors:  Timothy J Wallace; Junqi Qian; Itzhak Avital; Curt Bay; Yan-Gao Man; Laurie L Wellman; Chris Moskaluk; Dean Troyer; Dharam Ramnani; Alexander Stojadinovic
Journal:  J Cancer       Date:  2018-06-04       Impact factor: 4.207

5.  Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.

Authors:  Wendy Mao; Ali Ghasemzadeh; Zachary T Freeman; Aleksandar Obradovic; Matthew G Chaimowitz; Thomas R Nirschl; Emily McKiernan; Srinivasan Yegnasubramanian; Charles G Drake
Journal:  J Immunother Cancer       Date:  2019-10-25       Impact factor: 13.751
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.